Microsatellite-stable, near-diploid (MSIÀCINÀ) colorectal carcinomas have been reported, but it is not clear as to whether these tumours form a discrete group or represent one end of the distribution of MSIÀCIN þ cancers. In order to address this question, we screened 23 MSIÀCINÀ colorectal cancers for gains and losses using array-based comparative genomic hybridization (aCGH) based on large-insert clones at about 1 Mb density. We compared our findings with those from a small set of MSI þ CIN þ cancers, and with our reported data from MSIÀCIN þ and MSI þ CINÀ cancers. We found no evidence of any form of genomic instability in MSIÀCINÀ cancers. At the level of the chromosome arm, the MSIÀCINÀ cancers had significantly fewer gains and losses than MSIÀCIN þ tumours, but more than the MSI þ CINÀ and MSI þ CIN þ lesions. The chromosomal-scale changes found in MSIÀCINÀ cancers generally involved the same sites as those in MSIÀCIN þ tumours, and in both cancer groups, the best predictor of a specific change was the total number of such changes in that tumour. A few chromosomal-scale changes did, however, differ between the MSIÀCINÀ and MSIÀCIN þ pathways. MSIÀCINÀ cancers showed: low frequencies of gain of 9p and 19p; infrequent loss of 5q and a high frequency of 20p gain. Overall, our data suggested that the MSIÀCINÀ group is heterogeneous, one type of MSIÀCINÀ cancer having few (p6) chromosomal-scale changes and the other with more (X10) changes resembling MSIÀCIN þ cancers. At the level of individual clones, frequent and/or discrete gains or losses were generally located within regions of chromosomal-scale changes in both MSIÀCINÀ and MSIÀCIN þ cancers, and fewer losses and gains were present in MSIÀCINÀ than MSIÀCIN þ tumours. No changes by clone, which were specific to the MSIÀCINÀ cancers, were found. In addition to indicating differences among the cancer groups, our results also detected over 50 sites (amplifications, potential homozygous deletion and gains or losses which extended over only a few megabases) which might harbour uncharacterized oncogenes or tumour suppressor loci. In conclusion, our data support the suggestion that some MSIÀCINÀ carcinomas form a qualitatively different group from the other cancer types, and also suggest that the MSIÀCINÀ group is itself heterogeneous.
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Introduction
The development of an accurate molecular classification for colorectal cancers is potentially of great importance for predicting outcome and for choosing therapies. The simplest such classification in common use is to divide colorectal carcinomas into microsatellite-unstable (MSI þ ) and MSIÀ types (Jass et al., 2002) ; the former is characterized by deficient DNA mismatch repair. MSI þ and MSIÀ colorectal tumours probably differ in their prognosis, their response to therapeutic regimens, and the genetic aberrations that they accumulate. MSI þ cancers generally have a near-diploid karyotype, with few large-scale genetic changes, whereas MSIÀ cancers are often held to be aneuploid and polyploid (or 'chromosomally unstable', CIN þ ). Very few cancers are both MSI þ and CIN þ .
More recently, three further groups of colorectal cancers have been proposed, although their featuresand perhaps even their existence -are more contentious than the well-established MSI þ /MSIÀ classification. First, a methylator phenotype, which overlaps considerably with the MSI þ category, may exist (Toyota et al., 1999; Yamashita et al., 2003) . Second, some have proposed that low-level MSI may exist in many cancers within the CIN þ group (Iino et al., 1999) . Third, a group of microsatellite-stable, near-diploid, (MSIÀCINÀ) colorectal carcinomas has been described (Georgiades et al., 1999; Curtis et al., 2000) . This phenotype, also known as MACS (microsatellite and chromosome stable), was originally reported by Georgiades et al. (1999) in four colorectal carcinomas. Subsequent studies have confirmed that MSIÀ, neardiploid colorectal cancers do exist, and have variously suggested that they account for up to a third of all bowel cancers, have aggressive behaviour and occur more often than expected in a familial context (Hawkins et al., 2001; Giaretti et al., 2003) . Conventional comparative genomic hybridization (CGH) has shown that MSIÀCINÀ cancers have fewer large-scale genetic aberrations than CIN þ carcinomas and may have fewer p53 mutations, although no specific MSIÀCINÀ molecular pathway has consistently been shown. No study has demonstrated, however, that MSIÀCINÀ cancers form a distinct group as opposed to one end of the distribution of MSIÀCIN þ lesions (our analysis of published data, Shapiro-Wilk test, details not shown).
Whilst conventional CGH has shown gross differences between MSIÀCINÀ and other colorectal cancers, this technique lacks sensitivity and resolution compared with newer methods, such as array-based CGH (aCGH). aCGH (Pinkel et al., 1998) can detect genetic changes at 1 Mb resolution or less, and can detect loss or gain of one copy of a clone in a tetraploid cell. aCGH has already confirmed the general findings from conventional CGH in MSI þ and CIN þ colorectal cancers (Douglas et al., 2004; Nakao et al., 2004) , and has detected previously uncharacterized changes in these tumours. We have used genome-wide aCGH to screen a set of 23 MSIÀCINÀ colorectal carcinomas. Our study had three aims: first, to compare and contrast the genetic pathways in MSIÀCINÀ and other types of colorectal carcinoma; second, to identify relatively small chromosomal regions within which uncharacterized oncogenes or tumour suppressor loci may lie; and third, to examine MSIÀCINÀ cancers for uncharacterized forms of genomic instability, which may be detectable using aCGH. We have compared our results with findings from a small set of MSI þ CIN þ tumours and with our existing data from MSI þ CINÀ and MSIÀCIN þ cancers. We have assessed associations between changes detected by aCGH and clinicopathological-molecular variables. Our results help to suggest whether or not MSIÀCINÀ colorectal carcinomas comprise a qualitatively distinct group of tumours.
Results
We grouped cancers according to ploidy and microsatellite instability. We identified 23 near-diploid, microsatellite stable (MSIÀCINÀ) cancers, 30 aneuploid/polyploid, microsatellite-stable (MSIÀCIN þ ) cancers, two MSI þ CIN þ cancers and five MSI þ CINÀ cancers. MSIÀlow cancers were not defined as a separate group for the purposes of this study. The frequencies of K-ras mutations did not differ significantly between MSIÀCINÀ (7/22 mutant) and MSIÀCIN þ (8/30 mutant) cancers (P ¼ 0.46, Fisher's exact test). No clinicopathological differences between MSIÀCINÀ and MSIÀCIN þ cancers were found.
From the aCGH analysis, we initially considered large-scale changes involving a chromosome arm or large part thereof (henceforth referred to as 'chromosomal-scale changes'). Overall, for the 39 autosome arms, the cancers showed 272 chromosomal-scale gains (11.6%) and 340 losses (14.5%). The 30 MSIÀCIN þ cancers showed the highest frequency of large gains and losses (16.5 and 20.5%, respectively), followed by MSIÀCINÀ tumours (7.2 and 10.4%), MSI þ CIN þ tumours (5.1 and 9.0%) and MSI þ CINÀ tumours (5.1 and 0%). These differences were statistically significant (for gains, w 3 2 ¼ 55 overall, Po0.001; for losses, w 3 2 ¼ 81 overall, Po0.001). The MSIÀCINÀ group had a significantly lower frequency of gains and losses than the MSIÀCIN þ group and a lower frequency of losses than the MSI þ CINÀ group (all Po0.001, Wilcoxon's rank sum test). There was heterogeneity among groups in their tendency to gains versus losses (w 3 2 ¼ 13.5 overall, P ¼ 0.004), owing solely to the over-representation of gains in the MSI þ CINÀ cancers. The frequencies of chromosomal-scale gains and losses in the main cancer types are shown in Figure 1 .
In all cancer groups combined, the most frequent chromosomal-scale changes were gain of 20q (68% of tumours), loss of 18q (65%), gain of 13q (55%), loss of 17p (53%), loss of 18p (52%), loss of 8p (47%), loss of 22q (37%), gain of 8q (33%), loss of 14q (32%), gain of 7p (30%), gain of 20p (28%), loss of 1p (25%), loss of 4q (25%), gain of 5p (23%), loss of 5q (22%) and loss of 15q (22%). Some chromosomal-scale changes tended to occur together. Loss of gain of both arms of a chromosome was frequently found, presumably as a result of whole chromosome mis-segregation. 'Opposite' changes on the same chromosome, perhaps owing to isochromosome formation, were also observed significantly more often than expected, namely: gain of 5p and loss of 5q (P ¼ 0.001, Fisher's exact text); 8p loss and 8q gain (Po0.001); 17p loss and 17q gain (P ¼ 0.004) and 20p loss with 20q gain (P ¼ 0.012). Pairwise analysis showed that several other changes tended to occur together, with strongest evidence for cooccurrence of (i) loss of 8p and loss of 20q, (ii) gain of 8q and loss of 15q, (iii) loss of 17p and loss of 18p and/or 18q (for each, Po0.01 overall and Po0.05 in MSIÀ cancers only); these associations may have resulted from coselection of changes in specific genetic pathways, or from variation among cancers in the extent of CIN.
We determined whether any specific loss or gain at the level of the chromosome arm was over or underrepresented in any of the cancer types; we focused on MSIÀCINÀ cancers in comparison with MSIÀCIN þ tumours, owing to the smaller number of tumours in the other two groups. We reasoned that chromosome changes would tend to be over-represented in certain tumours as a result of a general tendency to CIN. We therefore controlled for this factor using logistic regression analysis, with both cancer types (MSIÀCINÀ versus MSIÀCIN þ ) and the overall frequency of changes in each tumour as independent variables in the test, and loss or gain of a specific chromosome arm as the dependent variable. We found that several chromosome arm changes (gains of 1q, 6q, 7p, 7q, 13q, 16p, 16q, 17q, 20q; losses of 1p, 4p, 4q, 5q, 8p, 10q, 14q, 15q, 17p, 18p, 20p, 21q, 22q) were associated (all Po0.05) with the overall number of changes in that cancer (i.e., the level of nominal CIN), but not with cancer type. (Incorporation of a measure of hybridization quality into the regression model showed that this had no effect on the presence of chromosomal-scale Analysis of changes at individual clones showed that 7.8% of clones reported gain and 5.0% reported loss overall. Hybridization quality did not vary significantly among the four tumour types (details not shown). Copy number changes involved widely varying lengths of each chromosome, from single clones upwards. Overall, linear regression analysis showed the number of clones gained and lost within each tumour to be strongly associated with each other for all cancer groups combined (t ¼ 5.16, Po0.001). Changes were most common in MSIÀCIN þ cancers (13.3% clones gained, 8.55% lost), followed by the MSI þ CIN þ (10.8% gain, 6.52% loss), MSIÀCINÀ (4.94% gain, 3.33% loss) and MSI þ CINÀ groups (3.66% gain, 2.79% loss); for both losses and gains, these frequencies were significantly different, both overall (Po0.001, w 2 test). and for comparisons between all groups pairwise (Po0.035 or lower, w 2 test). These significant differences remained when data were corrected for the quality of an individual hybridization using multiple linear regression analysis (details not shown). There was heterogeneity among cancer groups in their tendency to gains versus losses (w 3 2 ¼ 471 overall, Po0.001), with gains relatively common in the two CIN þ types of cancer. The genome-wide frequencies of loss and gain at each clone in the MSIÀ cancer types are shown in Figure 2 . An illustrative genomewide plot of copy number ratios is shown for the MSIÀCINÀ cancer no. 1351 in Figure 3 .
Individual clones reporting the most frequent gains and losses (>40%) in each cancer type (excepting the rare MSI þ CIN þ tumours) are shown in Table 1 . As expected from the analysis at the level of the chromosome arm, gains were detected frequently on chromosomes 13q, 20p and 20q. Clone losses were found frequently, as expected, on chromosomes 1p, 4q, 5q, 8p, 14q, 17p, 18p and 18q. The frequency of gain on 6p was higher by clones in the MSIÀCIN þ cancers than predicted from the chromosome-level analysis, because a region of only about 16 Mb was involved. In many cases, the frequency data by clones suggested peaks of higher frequency loss within regions that were commonly lost on a chromosomal scale (e.g., 17p loss at 6.1-9.5 and 13.0-15.4 Mb in MSIÀCIN þ cancers; Table 1, Figure 1 ). In addition to the generally predicted changes, many smaller regions of frequent loss or gain, which were not present in the chromosomal-scale analysis, were suggested by analysis of individual clones (e.g., loss at 111.7-115.0 Mb on chromosome 1q, and gain at 17.9-25.1 Mb on 20p; Table 1, Figure 1) . Additional work will be required to determine whether or not a higher frequency of loss or gain at a clone, compared with surrounding clones, truly implies that the primary target of the change lies at this site, as opposed to alternative explanations, such as chance variation or clones with high sensitivity (e.g., with low numbers of repeat sequences).
The data from individual clones suggested some differences among cancer types although few which were not also apparent at the chromosomal level (Table 1) . Clone RP11-248L3 (chromosome 17, 51.5 Mb) was gained in 78% of MSIÀCINÀ cancers, but was gained in 20% of MSIÀCIN þ cancers and no MSI þ CIN þ cancers. Many individual gains were frequent in the MSI þ CINÀ cancers, although the small numbers in this group suggest caution in interpreting these data.
Using our threshold of >1.58, we detected 16 regions of possible amplification (Table 2) . Although most of the changes were found in MSIÀCIN þ cancers, involved single clones and occurred in only one tumour, they are still good candidate sites for the locations of oncogenes; several of the possible amplifications were found in regions that were known to be frequent sites of lower level gains, such as 8q and 20q (Table 1) . Of particular note were: gains on 17q 12 in two cancers, one involving more than one clone; and four other amplifications in different tumours, which involved multiple clones ( Table 2 ). The only possible HOD in our cancers occurred at a location on 13q, which was also amplified in one cancer and might therefore be a previously undetected polymorphism.
We then searched for relatively small, discrete regions of loss or gain, which might aid in mapping tumour genes. Our criteria were that the region should involve 2-7 clones reporting the same change and that dosage change should differ significantly from the flanking clones. Table 3 shows 34 discrete gains and 45 discrete losses identified by this process. Most changes were found in only one cancer, although many occurred in regions of frequent loss or gain, and therefore represent candidate locations for the genes targeted by these changes; examples include gains on chromosomes 8, 13 and 20, and losses on chromosomes 1, 3, 4, 5, 8, 14, 17, 18, 21 and 22 (Table 3, Figures 1 and 2) . Certain discrete changes were found in more than one cancer, namely: gain of 8q21.13 at around 84 Mb; gain of 9q34.13 at around 130 Mb; gain of 10q at 89.8 Mb and loss at about 80 Mb; loss of 17q24.3 at about 71.2 Mb; and gain of 21q22.3 at about 43 Mb. Potential small overlapping regions of change were detected close to 95.5 Mb on chromosome 2q11.1 (loss) and 61 Mb on chromosome 20q13.33 (loss). Each of the discrete changes was too rare to allow a useful comparison among cancer types.
Two MSIÀCIN þ cancers provided evidence suggestive of an additional form of underlying genomic instability (details not shown). Tumour #571 showed gain of multiple telomeric regions. Tumour #643 contained multiple, 'punched out' areas of loss, typically comprising a few Mb. These cancers were otherwise unremarkable as regards their genetic changes. No evidence was detected for any novel form of genetic instability in the MSIÀCINÀ cancers.
The two MSI þ CIN þ cancers showed no chromosomal scale or discrete gains or losses in one case (#1542) and, in the other (#1492), a small number of changes (gain of 5p, 6 and 13q, loss of 4, 5q, 15q, 16 and 22q, and two discrete losses at 70.9-72.6 Mb on chromosome 11 and 92.9-96.8 Mb on chromosome 14). No genetic features specific to this tumour type were found.
Inspection of the data, especially changes at the level of the chromosome arm, raised the possibility that there was heterogeneity within and/or overlap between our four groups of cancer, especially the MSIÀCIN þ and MSIÀCINÀ groups. This suggestion was further supported by the finding that, while certain changes did differ between MSIÀCIN þ and MSIÀCINÀ cancers, the strongest predictor of a change at the chromosome arm level was the total number of changes in that cancer (see above). MSIÀCINÀ cancers, moreover, had a far higher frequency of chromosomal-scale changes than MSI þ CINÀ cancers, which they might be expected to resemble karyotypically. While the total number of chromosomal-scale changes was normally distributed in MSIÀCIN þ cancers (Shapiro-Wilk test, P ¼ 0.94), there was evidence for non-normality in the MSIÀCINÀ cancers which appeared to follow a bimodal distribution ( Figure 4a ); 12 cancers with few (p6) changes were in one group and the remaining 11 cancers with more (X10) changes were in another. The 
Discussion
We have compared genome-wide array CGH profiles of 23 MSIÀCINÀ colorectal cancers with our published data on MSIÀCIN þ and MSIÀCINÀ cancers. We have also reported on two MSI þ CIN þ cancers. Our purposes were threefold: first, to compare the genetic pathways in different types of colorectal carcinoma; second, to attempt to identify relatively small chromosomal regions within which uncharacterized oncogenes or tumour suppressor loci may lie; and third, to identify underlying, uncharacterized genomic instability in MSIÀCINÀ cancers.
Large (chromosomal-scale) and small (individual clone) changes were most common in the MSIÀCIN þ þ cancers, followed by MSIÀCINÀ MSI þ CIN þ MSIÀCIN þ and MSI þ CINÀ tumours. These differences were observed for both losses and gains, with a striking absence of large-scale losses in the MSI þ CINÀ group. At the chromosomal level, we confirmed changes detected previously using conventional CGH and allelic loss analysis in colorectal cancer, such as loss of 1p, loss of 5q, loss of 8p, gain of 13q, loss of 17p, loss of 18q and gain of chromosome 20. Overall, the best predictor of a particular chromosome arm change in any cancer was the total number of changes in that cancer; this finding suggests, but no more, that many large changes in colorectal cancers are 'background noise'. Certain changes were, however, independently associated with MSIÀCINÀ (no gain of 9p, no gain of 19p, no loss of 5q and increased loss of 20p). Analysis of the frequencies of gains and losses at individual clones confirmed the larger-scale changes reported, and suggested smaller regions within which the target genes might lie. Differences between the frequencies of change at individual clones were observed among cancer types, although the significance of these differences requires further investigation.
For the purposes of gene mapping, aCGH suggested small regions of amplification or HOD, discrete regions Array-CGH analysis AM Jones et al Locations of clones with T:N log 2 ratio>/o 1.58 are shown (position in Mb). The boundary clones represent the middle positions of the clones reporting amplification or HOD in that region. The number of adjacent clones gained or lost and the overall frequency of gain or loss within the amplicon or HOD are shown for comparison of loss or gain, and minimal regions of overlapping change. In most cases, these regions of change lay within larger regions that were commonly gained or lost in the whole cancer set. Any of the small regions that we have identified may harbour oncogenes or tumour suppressor loci with importance for colorectal tumorigenesis. The entire list of candidates is too long to list. However, known cancer genes within some of these regions include oncogenes cyclinD1 (Leach et al., 1993) and C-erbB2 (Gill et al., 2002; Pedowitz et al., 2003) and tumour suppressor genes PTEN (Guanti et al., 2000; Nassif et al., 2004) and TGFBR2 (Markowitz et al., 1995) , the last previously reported as specifically mutated in MSI þ cancers. Other good candidate cancer genes within our regions of change include possible oncogenes FGF9, cyclinE1 and BCL3. Two cancers (both MSIÀCIN þ ) showed unusual aCGH patterns, which suggested an additional, uncharacterised underlying type of genomic instability: one of these showed gain of multiple telomeric regions; and the other harboured several, 'punched out' losses of a few Mb. Exploration of changes in genes for telomere stability and double strand break formation/repair, respectively, might be fruitful in these cases. In contrast, despite hopes that the sensitivity of aCGH might reveal uncharacterized genomic instability -such as multiple, small gains or losses -in the MSIÀCINÀ cancers, no evidence of this was found, and it remains possible that these tumours do not have any form of genetic instability.
Colorectal cancers with both microsatellite instability and an aneuploid/polyploid karyotype have rarely been reported. Of the two MSI þ CIN þ cancers in our set, one resembled an MSI þ CINÀ cancer and the other harboured changes similar to MSIÀCINÀ lesions. We speculate that the former cancer developed from a MSI þ , near-diploid lesion as a result of polyploidisation with few further numerical changes; the latter Our data suggest that MSIÀCINÀ cancers might actually comprise two distinct groups; a dichotomy is most readily achieved in our set using a cutoff of 7-9 total chromosomal-level changes. Using this heuristic division, which was supported by cluster analysis, about half of the MSIÀCINÀ cancers resemble MSIÀCIN þ cancers, with multiple chromosomal changes, and the others are similar to MSI þ CINÀ cancers (in terms of few chromosomal changes and infrequent p53 mutations), but with absent MSI. We suspect that the former group of cancers may have acquired a near-diploid DNA content by chance balancing of gains and losses and/or that they may have a low level of aneuploidy, which cannot be detected using the resolution of flow cytometry. Perhaps MSIÀ CRCs should be classified by their actual chromosomal changes rather than by their DNA content.
We conclude that aCGH has identified several small regions of loss or gain, which may harbour tumour suppressors or oncogenes with roles in colorectal carcinogenesis. Fine mapping of these regions and complementary analyses, for example using expression microarrays, will be required in order to provide further evidence of the importance of these regions and to identify the loci involved. Some changes appear to be specific to cancers in the MSIÀCINÀ pathway, whereas others are found in cancers of more than one molecular type. At least some MSIÀCINÀ cancers appear to form a distinct group of tumours, and a small group of MSI þ CIN þ cancers also exists, showing that the MSI and CIN pathways are not mutually exclusive in colorectal cancer.
Materials and methods

Samples and baseline molecular data
An unselected series of 60 fresh-frozen colorectal carcinomas and paired normal bowel was obtained from St Mark's Hospital, London. All cancers contained more than 60% neoplastic cells, as assessed using routine histology. DNA was extracted from each sample using standard methods. For determination of ploidy, formalin-fixed, paraffin-embedded tissue was prepared by cutting a 50 mm section from each block, placing it into a histopathology cassette between two sheets of 3MM filter paper, and dewaxing it in 100% xylene (BDH) overnight. The section was rehydrated through an ethanol series (100, 95, 90, 70, 50%) and rinsed twice in water. The tissue was removed from the slide with a scalpel and digested with pepsin solution (0.5% pepsin (Sigma), 0.9% NaCl, pH 1.5) for 30 min at 371C. After centrifugation, at 1500 r.p.m. for 5 min at room temperature, cells were washed twice in PBS before flow cytometric analysis and detection of near-diploid and polyploid cell populations. For the flow cytometric analysis, we used the fact that all samples contained a small quantity of normal cells (as was apparent by microsatellite analyses on the same samples (data not shown)). Thus, if we saw only a single peak, the sample was classified as a near-diploid tumour. Previous control samples analysed on the same flow cytometer had shown that samples with greater than approximately a 10% increase or decrease in DNA content could readily be distinguished from truly diploid samples. Microsatellite instability was assessed using the mononucleotide repeat markers BAT25 and BAT26. Allelic bandshifts typical of MSI at either marker caused that cancer to be classed as MSI þ . Cancers were screened for mutations at K-ras (codons 12 and 13) using direct sequencing, using previously reported methods (Lipton et al., 2003) .
aCGH
The array construction and hybridization were performed as described by Fiegler et al. (2003) and Douglas et al. (2004) . In brief, the array was prepared from DOP-PCR amplified DNA from 3452 large insert genomic clones at an average spacing of abut 1 Mb throughout the genome. DNA from each of the cancers was labelled with Cy5-dCTP. DNA from a pool of normal individuals was used as a control and labelled with Cy3-dCTP. The test and normal DNAs were cohybridized to the arrays together with herring sperm and Cotl DNA and washed. The array was scanned using a confocal scanner (Perkin Elmer) and Spot (Jain et al., 2002) software was used to process the images. After rejecting poorly hybridized arrays by visual inspection of scans and correcting for background, the log 2 ratio of the fluorescence intensities of test (tumour, T) to reference (normal, N) was calculated, after normalization to the remainder of the genome in that tumour. Thus, a T:N log 2 ratio of zero implies no copy number change at that clone, a positive value indicates an increase in copy number and a negative value, a decrease in copy number; in practice, quantitation of gene dosage changes in frozen tumour specimens is rendered difficult by the presence of 'normal' contaminating tissue in each sample. The determination of significant copy number changes was performed as described by Douglas et al. (2004) . In brief, T:N log 2 ratio thresholds for identifying clones which deviated significantly (at Po0.01) from a ratio of 1 were derived from a panel of normal versus normal hybridizations. Hybridization quality of individual experiments was then taken into account by identifying regions of modal copy number in that cancer. Within that cancer, variation of the defined modal region was used to set thresholds specific to that hybridization for significant gain or loss of material. In addition to simple gain or loss, possible amplifications and homozygous deletions (HODs) were scored if a T:N log 2 ratio was 71.58, an essentially arbitrary threshold corresponding to a theoretical three-fold copy number change. Copy number changes of the sex chromosomes were not analysed.
Statistical analysis
Statistical analysis was performed using STATA 7.0. Below, we report all associations detected at Po0.05 or lower. In a small number of analyses, notably when searching for associations with subchromosomal scale changes, multiple testing is inherent, suggesting that in these specific cases, associations should be regarded with caution unless a significance level of Po0.01 or lower is reported.
